18 results about "Gambogic acid" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses application of gambogic acid in preparation of a medicine for treating ulcerative colitis. The gambogic acid provided by the invention can be used for preparing a programmed necrosis inhibitor and a medicine for treating ulcerative colitis, and the gambogic acid is beneficial to improving cell morphology, increasing cell viability and improving symptoms of ulcerative colitis caused by DSS. Chemical structure of gambogic acid: # imgabs0 #

The invention discloses a multifunctional nano delivery system based on targeted ferritin as well as a preparation method and application of the multifunctional nano delivery system. According to the system, traditional Chinese medicine active ingredients, namely neogambogic acid GNA, a photosensitizer Ce6 and ferritin targeting peptide HKN15 are integrated through a self-assembly technology, a synergistic treatment system integrating photodynamic therapy PDT and ferroptosis induction is constructed, and the treatment effect on non-small cell lung cancer NSCLC can be remarkably enhanced. According to the nano delivery system, precise targeting of a tumor site is achieved through the ferritin targeting peptide HKN15, and a double anti-tumor mechanism is formed by utilizing the photodynamic effect of the photosensitizer Ce6 and the ferroptosis induction effect of GNA. The preparation process is based on a molecular self-assembly principle, and has the advantages of high tumor accumulation efficiency, low system toxicity, remarkable tumor inhibition effect and the like, and an innovative solution is provided for precise treatment of the non-small cell lung cancer.

The invention discloses a 3D bio-printing sustained-release microneedle patch used after brain glioma surgery and a preparation method thereof.The microneedle patch is prepared by compounding GFD nano-enzyme and a hydrogel base material, the GFD nano-enzyme is gambogic acid-iron-adriamycin nano-enzyme, and the hydrogel base material is a hydrogel base material. The hydrogel base material is composed of photo-crosslinking gelatin (GelMA), methacrylic hyaluronic acid (HAMA), a photoinitiator and an ultraviolet absorbent, the microneedle patch is of a conical microneedle array structure, the interior of the microneedle patch is of a porous structure, and GFD nano-enzyme is evenly distributed in microneedles. The application potential of the existing 3D biological printing and nano-enzyme technology and the technical advantages of 3D biological printing are adopted, by means of the 3D biological printing technology with high-dimensional manufacturing precision, the microneedle array structure is designed and printed in a customized mode according to the irregular shape of the tumor residual cavity of a patient, complete attachment to the wall of the residual cavity is achieved, and the dead cavity effect is solved; meanwhile, the technology can accurately regulate and control the shape, the size and the drug loading capacity of the microneedle, and provides possibility for personalized treatment.

The invention relates to the technical field of nano medicine, in particular to iron gambogic acid adriamycin nano particles, a preparation method and application. Gambogic acid, doxorubicin hydrochloride and an iron-containing compound are matched, carbonyl oxygen and hydroxyl in the gambogic acid and Fe < 3 + > form coordinate bonds, carbonyl and amino in the doxorubicin hydrochloride and a conjugated system in a benzene ring are combined with Fe < 3 + > through covalent bonds and pi-pi accumulation, a core-shell structure is formed, and the iron gambogic acid doxorubicin nano-particles are obtained. The particle size of the iron gambogic acid adriamycin nano-particles ranges from 2 nm to 10 nm. The iron gambogic acid adriamycin nano-particles have excellent multi-enzyme activity, autophagy amplification is effectively achieved, traditional chemotherapy drug resistance caused by autophagy is overcome, and the glioma chemotherapy effect is improved.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine resistance. The pharmaceutical composition is prepared from active ingredients such as a radix sophorae flavescentis extract, a poria cocos extract, emodin, glucosamine, gambogic acid, tranilast and aspirin. The preparation method of the sophora flavescens extract and the poria cocos extract comprises the steps of raw material pretreatment, dynamic ultrasonic-microwave synergistic extraction, membrane separation and nanofiltration, high-efficiency countercurrent chromatography purification, vacuum low-temperature concentration, drying and the like. The pharmaceutical composition can be prepared into a plurality of pharmaceutical preparations such as tablets, capsules, granules, cream, injections and the like. The invention further provides a preparation method of the oral tablet for reversing pancreatic cancer gemcitabine drug resistance, and the pharmaceutical composition has a remarkable treatment effect on a drug resistance mechanism formed by up-regulating expression of SREBP1 by histone lactylation mediated PKM2 through an AKT / mTOR pathway. The pharmaceutical composition provided by the invention provides a new treatment choice for pancreatic cancer patients, and has an important clinical application value.

The invention discloses a ginsenoside Rg3-gambogic acid co-assembled nanoparticle which is prepared by co-assembling ginsenoside Rg3 and gambogic acid, and a preparation method of the ginsenoside Rg3-gambogic acid co-assembled nanoparticle. The ginsenoside Rg3-gambogic acid co-assembled nanoparticles can effectively increase the delivery rate of drugs, improve the solubility of gambogic acid, have a good anti-cancer effect, and have a better effect compared with a single drug of the same dosage. Meanwhile, the ginsenoside Rg3-gambogic acid co-assembled nanoparticles disclosed by the invention realize carrier-free pure drug self-delivery, and the delivery efficiency is improved. The invention discloses an application of the ginsenoside Rg3-gambogic acid co-assembled nanoparticles in preparation of an anti-tumor drug, and further discloses a preparation method of the ginsenoside Rg3-gambogic acid co-assembled nanoparticles.

The invention belongs to the technical field of medicines, and particularly relates to a microneedle patch for disguising a macrophage cell membrane and a preparation method of the microneedle patch. Degradable high polymer material nano-particles camouflaged by the macrophage membrane are embedded in a microneedle array of the microneedle patch camouflaged by the macrophage membrane, and the degradable high polymer material nano-particles camouflaged by the macrophage membrane are wrapped with gambogic acid and oleic acid functionalized cerium dioxide nano-particles. Nanoparticles of the microneedle patch jointly load gambogic acid and oleic acid functionalized cerium dioxide, through microneedle transdermal drug delivery, active targeting of the drug to the liver is achieved by using natural inflammatory taxis of a macrophage membrane, the anti-inflammatory effect of gambogic acid and the anti-oxidation effect of cerium dioxide are synergistically exerted, polarization of macrophages is adjusted, and the anti-inflammatory effect of the drug on the liver is achieved. Therefore, the liver injury caused by the septic shock is treated.

The invention discloses a preparation method and application of esterase sensitive gambogic acid self-assembled micelle nanoparticles. Gambogic acid and poloxamer 188 are used as raw materials of the self-assembled micelle nanoparticle, and GA and P188 form an ester bond through esterification reaction, so that a gambogic acid self-assembled micelle nanoparticle precursor is formed. The gambogic acid micelle nanoparticles can be formed through self-assembly in an aqueous solution, the particle size is uniform, the average particle size is about 58 nm, the polydispersity index is 0.203, and it is indicated that the micelle nanoparticles have good monodispersity. In-vitro release studies show that the prepared gambogic acid self-assembled micelle nanoparticles have esterase responsiveness and are expected to realize targeted release of gambogic acid at tumor sites, and the anti-tumor effect is improved. The preparation method of the gambogic acid self-assembled micelle nanoparticle GA-P188 provided by the invention is simple in operation steps, relatively low in cost and good in tumor inhibition effect, and can have relatively high industrialization prospects.

The invention discloses a preparation method of IR780 and gambogic acid prodrug-loaded lipidosome, which comprises the following steps: dissolving mPEG-TK-NH2 in dimethylformamide, adding gambogic acid, benzoyl peroxide and triethylamine, stirring for reaction, concentrating and recrystallizing to obtain mPEG-TK-GA, adding mPEG-TK-GA, soybean phosphatidylcholine, cholesterol and IR780 into an organic solvent, and carrying out rotary evaporation to remove the organic solvent, thereby obtaining the IR780 and gambogic acid prodrug-loaded lipidosome. The SIRP-alpha gene engineering exosome preparation method comprises the following steps: preparing a lipid membrane, adding a phosphate buffer solution, heating, carrying out ultrasonic treatment, granulating to obtain a liposome solution, mixing an SIRP-alpha gene engineering exosome and IG Lipo, and carrying out membrane fusion by adopting a freeze-thaw method to obtain the SIRP-alpha gene engineering exosome preparation. Compared with the prior art, the liposome prepared by the method has a responsive drug release effect, can relieve toxic and side effects while improving the treatment effect, is also loaded with IR780, and can reduce the dosage and improve the treatment effect in combination with photothermal therapy.

The invention belongs to the field of plant planting, and particularly relates to a method for improving saline-alkaline tolerance of plants. According to the specific technical scheme, the method for helping seed germination under saline-alkali stress comprises the following steps: soaking seeds in dihydrocoumarin, gambogic acid, 2-aminonicotinic acid or triptolide, or applying dihydrocoumarin, gambogic acid, 2-aminonicotinic acid or triptolide to the vicinity of a plant root system to be treated. It is found for the first time that 2-aminonicotinic acid, gambogic acid, dihydrocoumarin and triptolide have the capability of enhancing the saline-alkaline tolerance of plants at low concentration, so that the 2-aminonicotinic acid, gambogic acid, dihydrocoumarin and triptolide have the potential as plant growth regulators or plant biostimulants.

The invention discloses a gambogic acid B targeting lncRNA GAS5 nano-delivery system, and belongs to the technical field of pharmaceutical preparations, and the gambogic acid B targeting lncRNA GAS5 nano-delivery system comprises gambogic acid B; a solid lipid; a liquid lipid; a surfactant; a phospholipid; a targeting ligand modified polyethylene glycol lipid; wherein the targeting ligand modified polyethylene glycol lipid comprises folic acid modified polyethylene glycol lipid and CD44 antibody modified polyethylene glycol lipid. The gambogic acid B targeting lncRNA GAS5 nano delivery system provided by the invention has remarkable advantages in the aspects of enhancing gastric cancer targeting, improving drug delivery efficiency, inhibiting gastric cancer metastasis and prolonging survival time.

The invention relates to the technical field of medicines, in particular to gambogic acid-manganese nanoparticles and application thereof. The gambogic acid-manganese nanoparticles are mainly obtained by combining a complex of gambogic acid and divalent manganese ions with an oxidation-sensitive high-molecular polymer; a monomer for preparing the oxidation-sensitive high-molecular polymer comprises an ROS responsive structural unit with a thioketal group; monomers for preparing the oxidation-sensitive high-molecular polymer further comprise 1, 2, 4, 5-cyclohexane tetracarboxylic dianhydride and a water-soluble group.

The invention provides a preparation process route of a gambogic acid-glucose conjugate with antitumor activity. According to the technical scheme, hemiacetal hydroxyl on glucose firstly reacts with a connecting chain with bifunctional groups, the obtained product serves as an initial raw material of the process route and then is coupled with carboxyl on gambogic acid, and the gambogic acid-glucose conjugate is prepared. The reaction raw material related to glucose is 2-(acetoxymethyl)-6-(bromo alkoxy) tetrahydro-2H-pyran-3, 4, 5-triacetate or 2-(azido alkoxy)-6-(hydroxymethyl) tetrahydro-2H-pyran-3, 4, 5-triol, the reaction raw material is provided with an alkyl long chain, and the reaction raw material related to glucose is 2-(acetoxymethyl)-6-(bromo alkoxy) tetrahydro-2H-pyran-3, 4, 5-triacetate or 2-(azido alkoxy)-6-(hydroxymethyl) tetrahydro-2H-pyran-3, 4, 5-triol or 2-(azido alkoxy)-6-(hydroxymethyl) tetrahydro-2H-pyran-3, 4, 5-triol. The 2-(azido alkoxy)-6-(hydroxymethyl) tetrahydro-2H-pyran-3, 4, 5-triacetate can be directly connected with the carboxyl group of gambogic acid, and the 2-(azido alkoxy)-6-(hydroxymethyl) tetrahydro-2H-pyran-3, 4, 5-triol can be connected with the carboxyl group of gambogic acid through an omega-bromo alkyl alkyne chain. The selected preparation process route is mild in reaction condition, high in yield, low in cost and suitable for industrial production.

The invention discloses a nanoparticle of ferritin co-carrying IR808 and gambogic acid with the surface modified with tumor penetrating peptide and a preparation method and application thereof, the nanoparticle comprises a carrier, and the carrier is ferritin; the targeting part is a tumor penetrating peptide covalently modified on the surface of ferritin, and a connection site is a ferritin surface sulfydryl; the carried objects are a photosensitizer IR808 and gambogic acid, and the carried objects are loaded in the inner cavity of the cage-shaped structure of the ferritin. Compared with non-modified ferritin, the RGE-ferriprotein-IR808-gambogic acid nano particle provided by the invention has the advantages that the tumor cell uptake capability is enhanced; compared with the chemotherapy or phototherapy of a ferritin single-loading drug, the anti-tumor effect of the ferritin co-loading two drugs is better, the chemotherapy and the photothermal / photodynamic therapy have a synergistic effect, and the ferritin co-loading two drugs have a wide application prospect in the aspect of tumor treatment.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.

The invention belongs to the technical field of biological medicines, and particularly relates to application of gambogic acid combined with imatinib in preparation of a medicine for treating gastrointestinal stromal tumor. The gambogic acid and the imatinib are jointly applied to treatment of the gastrointestinal stromal tumor, and compared with an existing single imatinib treatment scheme, the gambogic acid and the imatinib can form a synergistic anti-tumor effect, so that the sensitivity of gastrointestinal stromal tumor cells to the imatinib is effectively improved, the problem that the drug effect is insufficient possibly existing when a single drug is used is solved, and the curative effect of the gastrointestinal stromal tumor is improved. And the overall treatment effect is improved. The gambogic acid and imatinib are combined to further inhibit the activity and proliferation of gastrointestinal stromal tumor cells and induce tumor cell apoptosis, so that the gastrointestinal stromal tumor resisting effect is enhanced. Therefore, the invention provides a new strategy and choice for the drug treatment of gastrointestinal stromal tumor, and has important clinical application value.

Provided here are compositions and methods for management of human papillomavirus-associated cancers. One such method of treating a human papillomavirus-associated cancer in a subject includes administering to the subject a therapeutically effective amount of gambogic acid or 30-hydroxygambogic acid or a pharmaceutically acceptable derivative thereof. These methods can also include administering one or more of radiation or a chemotherapeutic agent.

This application relates to the preparation and application of a gambogeylic acid formulation targeting malignant tumors. It employs a three-layer structure: the core is a gambogeylic acid-black phosphorus quantum dot complex, possessing both chemotherapy and photothermal therapy functions; the middle layer consists of cryogenically frozen NK92 MI cell-derived nanovesicles, providing natural immune targeting and killing capabilities; the outer shell is a hyaluronic acid chelate, enabling active targeting and pH / photothermal responsive drug release. The core of its preparation method lies in using coaxial electrospray technology to form the three layers in one step, resulting in a highly efficient process and good formulation stability. This formulation can achieve synergistic photothermal-chemo-immunotherapy and simultaneously possesses near-infrared fluorescence and photoacoustic multimodal imaging capabilities, effectively solving the problems of poor targeting, significant toxic side effects, and lack of real-time monitoring associated with traditional chemotherapy. It demonstrates significant advantages and application potential in the precision treatment and diagnosis of solid tumors.